首页 | 本学科首页   官方微博 | 高级检索  
检索        

散结镇痛胶囊入血成分治疗子宫内膜异位症、子宫腺肌症及继发性痛经的作用机制探讨
引用本文:苏真真,柯志鹏,张新庄,曹亮,王振中,肖伟.散结镇痛胶囊入血成分治疗子宫内膜异位症、子宫腺肌症及继发性痛经的作用机制探讨[J].中国实验方剂学杂志,2019,25(17):165-172.
作者姓名:苏真真  柯志鹏  张新庄  曹亮  王振中  肖伟
作者单位:江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000,江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000,江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000,江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000,江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000,江苏康缘药业股份有限公司, 中药制药过程新技术国家重点实验室, 江苏 连云港 222000
基金项目:国家“重大新药创制”科技重大专项(2013ZX09402203)
摘    要:目的:分析散结镇痛胶囊治疗子宫内膜异位症、子宫腺肌症及继发性痛经的活性成分群和分子作用机制。方法:将散结镇痛胶囊的入血成分与子宫内膜异位症、子宫腺肌症及继发性痛经相关的靶点进行分子对接,选取对接得分较高的分子与靶蛋白构建药物-靶点网络图,分析网络特征。结果:网络分析结果表明散结镇痛胶囊中的6个成分可与子宫内膜异位症、子宫腺肌症及继发性痛经的87个靶点有较强的相互作用,进一步的分析阐明了散结镇痛胶囊的5个主要活性成分及23个潜在作用靶点。结论:散结镇痛胶囊的主要活性成分通过作用于炎症反应、细胞侵袭、凝血系统、平滑肌收缩、神经激素调节等靶点,来抑制子宫内膜的血管形成和血液循环、子宫平滑肌收缩、免疫炎症反应以及雌激素分泌,达到治疗子宫内膜异位症、子宫腺肌症及继发性痛经等病证的目的。

关 键 词:散结镇痛胶囊  网络药理学  子宫内膜异位症  子宫腺肌症  继发性痛经
收稿时间:2019/1/7 0:00:00

Molecular Mechanism of Sanjie Zhentong Capsule in Treatment of Endometriosis, Adenomyosis, Secondary Dysmenorrhea
SU Zhen-zhen,KE Zhi-peng,ZHANG Xin-zhuang,CAO Liang,WANG Zhen-zhong and XIAO Wei.Molecular Mechanism of Sanjie Zhentong Capsule in Treatment of Endometriosis, Adenomyosis, Secondary Dysmenorrhea[J].China Journal of Experimental Traditional Medical Formulae,2019,25(17):165-172.
Authors:SU Zhen-zhen  KE Zhi-peng  ZHANG Xin-zhuang  CAO Liang  WANG Zhen-zhong and XIAO Wei
Institution:Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China,Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China,Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China,Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China,Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China and Jiangsu Kanion Pharmaceutical Co. Ltd., State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang 222000, China
Abstract:Objective: To analyze the pharmacological basis and molecular mechanism of Sanjie Zhentong capsule in the treatment of endometriosis, adenomyosis, secondary dysmenorrhea. Method: The 6 compounds of Sanjie Zhentong capsule showed stronger interactions with 87 proteins relating to endometriosis, adenomyosis, and secondary dysmenorrhea in molecular docking. Then the drug-target network was selected, and the network features were analyzed. Result: The molecular docking and network characteristics revealed 5 main active molecules and 23 potential targets of Sanjie Zhentong capsule. Conclusion: The main active ingredients of Sanjie Zhentong capsule have a trong inhibition effect on endometrial angiogenesis and blood circulation, uterine smooth muscle contraction, immune inflammatory reaction and estrogen secretion by acting on the targets of inflammation, cell invasion, metastasis, coagulation system, smooth muscle contraction and neurohormone regulation, so as to treat endometriosis, adenomyosis and secondary dysmenorrhea.
Keywords:Sanjie Zhentong capsule  network pharmacology  endometriosis  adenomyosis  secondary dysmenorrheal
本文献已被 CNKI 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号